TIGIT and neoplasm: Tumour-infiltrating lymphocytes (TIL) express high levels of TIGIT and blocking antibodies that inhibit the TIGIT-Nectin interaction have demonstrated pre-clinical and clinical tumour control8–11, facilitating a growing number of clinical trials targeting TIGIT across multiple cancers12.